Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

被引：47

作者：

Chau, Ian

Doki, Yuichiro

Ajani, Jaffer A.

Xu, Jianming

Wyrwicz, Lucjan

Motoyama, Satoru

Ogata, Takashi

Kawakami, Hisato

Hsu, Chih-Hung

Adenis, Antoine

El Hajbi, Farid

Di Bartolomeo, Maria

Freitas Melro Braghiroli, Maria Ignez

Holtved, Eva

Xynos, Ioannis

Liu, Xuan

Lei, Ming

Kondo, Kaoru

Kato, Ken

Kitagawa, Yuko

机构：

[1] Royal Marsden Hosp, Sutton, Surrey, England

[2] Osaka Univ, Grad Sch Med, Osaka, Japan

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Acad Mil Med Sci, Affiliated Hosp, Ctr Canc, Beijing, Peoples R China

[5] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland

[6] Akita Univ Hosp, Akita, Japan

[7] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[8] Kindai Univ, Fac Med, Osakasayama, Japan

[9] Natl Taiwan Univ Hosp, Taipei, Taiwan

[10] Inst Canc Montpellier, Montpellier, France

[11] Ctr Oscar Lambret, Lille, France

[12] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[13] Univ Sao Paulo, Inst Canc Sao Paulo, Sao Paulo, Brazil

[14] Odense Univ Hosp, Odense, Denmark

[15] Bristol Myers Squibb, Princeton, NJ USA

[16] Natl Canc Ctr, Dept Head & Neck Med Oncol, Tokyo, Japan

[17] Keio Univ, Sch Med, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 18期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.LBA4001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4001

引用

页数：3